Investigating small molecule treatments for Krabbe disease
Characterization of Small Molecule Therapeutic Agents for a Lysosomal Leukodystrophy
This study is looking for new treatments for Krabbe disease, a serious brain condition, by testing small medicines that can lower harmful levels of a substance in the brain, with the hope of helping people live better lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10704476 on NIH RePORTER |
What this research studies
This research focuses on Krabbe disease, a severe neurological condition caused by a genetic deficiency that leads to toxic levels of a substance called psychosine in the brain. The researchers are developing small molecule therapies that can effectively cross the blood-brain barrier to reduce psychosine levels and potentially halt the progression of the disease. They have already identified promising therapeutic candidates through advanced screening methods using a specialized brain-derived cell line that mimics the disease's characteristics. The goal is to find effective treatments that can improve the quality of life for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants diagnosed with Krabbe disease or those at risk due to genetic factors.
Not a fit: Patients with other neurological disorders unrelated to lysosomal storage diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve outcomes for patients with Krabbe disease.
How similar studies have performed: Previous research has shown promise in using small molecules to target similar neurological conditions, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Maegawa, Gustavo Henrique Boff — Columbia University Health Sciences
- Study coordinator: Maegawa, Gustavo Henrique Boff
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.